We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
Read MoreHide Full Article
Phibro Animal Health Corporation (PAHC - Free Report) recently completed the acquisition of Zoetis Inc.’s (ZTS - Free Report) medicated feed additive (MFA) product portfolio and certain water-soluble products. The latest acquisition comes with a lineup of products across cattle, swine and poultry, which will complement and expand Phibro’s species and product portfolios. This will help the company’s customers meet the highest standards of animal care, prevent diseases and enhance nutrition around the world.
PAHC’s Likely Stock Trend Following the News
Subsequent to the news, the share price of PAHC remained unchanged at $23.12 at yesterday’s aftermarket trading.
The acquired product portfolio is expected to boost Phibro’s profitability and EBITDA margin and be accretive to its adjusted earnings per share. From investors’ viewpoint, the latest acquisition should expand and diversify Phibro’s revenue base, ultimately generating funds to support future investments in additional fast-growing animal health product categories. We expect the market sentiment to improve around the announcement.
Phibro currently has a market capitalization of $937.2 million. The company’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 4.10%.
More on Phibro’s Acquisition
The purchase price of the acquisition was $350 million, subject to customary closing adjustments. The acquisition included a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the United States, Italy and China, and a team of more than 300 employees who primarily support the business's manufacturing and distribution activities. The acquired product portfolio generated approximately $400 million in revenues in 2023.
The latest acquisition broadens Phibro's solution options and expertise in supporting animal health globally. Meanwhile, it will help ensure that food is produced safely and sustainably for Phibro's consumers.
Industry Prospects Favor PAHC
Per a report from Market Research Future, the MFA market was valued at $14.90 billion in 2023 and is projected to grow $21.74 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.28% during the period. Factors such as reduced government office workers, delayed trade consignments, and farmers having less access to various items that were medicated feed additives will act as market drivers.
Image Source: Zacks Investment Research
Per a Techsci Research report, the global water soluble mineral and vitamin in feed market was valued at $4.38 billion in 2023 and is expected to witness a CAGR of 7.14% during 2023-2029. Key market growth drivers include increasing demand for animal products, technological advancements and an increasing focus on animal welfare.
Henceforth, Phibro’s latest acquisition turns out to be in favor of market prospects.
PAHC’s Price Performance
In the past year, PAHC’s shares have risen 106.6% compared with the industry’s 31.2% growth.
Phibro’s Zacks Rank and Other Key Picks
PAHC currently carries a Zacks Rank #1 (Strong Buy).
Boston Scientific’s shares have surged 69.3% in the past year. Estimates for the company’s earnings per share (EPS) have jumped 2.5% to $2.46 for 2024 and 2.2% to $2.77 for 2025 in the past 30 days. BSX’s earnings outpaced estimates in each of the trailing four quarters, delivering an average beat of 8.3%. In the last reported quarter, it posted an earnings surprise of 8.6%.
Estimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
Phibro Animal Health Corporation (PAHC - Free Report) recently completed the acquisition of Zoetis Inc.’s (ZTS - Free Report) medicated feed additive (MFA) product portfolio and certain water-soluble products. The latest acquisition comes with a lineup of products across cattle, swine and poultry, which will complement and expand Phibro’s species and product portfolios. This will help the company’s customers meet the highest standards of animal care, prevent diseases and enhance nutrition around the world.
PAHC’s Likely Stock Trend Following the News
Subsequent to the news, the share price of PAHC remained unchanged at $23.12 at yesterday’s aftermarket trading.
The acquired product portfolio is expected to boost Phibro’s profitability and EBITDA margin and be accretive to its adjusted earnings per share. From investors’ viewpoint, the latest acquisition should expand and diversify Phibro’s revenue base, ultimately generating funds to support future investments in additional fast-growing animal health product categories. We expect the market sentiment to improve around the announcement.
Phibro currently has a market capitalization of $937.2 million. The company’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 4.10%.
More on Phibro’s Acquisition
The purchase price of the acquisition was $350 million, subject to customary closing adjustments. The acquisition included a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the United States, Italy and China, and a team of more than 300 employees who primarily support the business's manufacturing and distribution activities. The acquired product portfolio generated approximately $400 million in revenues in 2023.
The latest acquisition broadens Phibro's solution options and expertise in supporting animal health globally. Meanwhile, it will help ensure that food is produced safely and sustainably for Phibro's consumers.
Industry Prospects Favor PAHC
Per a report from Market Research Future, the MFA market was valued at $14.90 billion in 2023 and is projected to grow $21.74 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.28% during the period. Factors such as reduced government office workers, delayed trade consignments, and farmers having less access to various items that were medicated feed additives will act as market drivers.
Image Source: Zacks Investment Research
Per a Techsci Research report, the global water soluble mineral and vitamin in feed market was valued at $4.38 billion in 2023 and is expected to witness a CAGR of 7.14% during 2023-2029. Key market growth drivers include increasing demand for animal products, technological advancements and an increasing focus on animal welfare.
Henceforth, Phibro’s latest acquisition turns out to be in favor of market prospects.
PAHC’s Price Performance
In the past year, PAHC’s shares have risen 106.6% compared with the industry’s 31.2% growth.
Phibro’s Zacks Rank and Other Key Picks
PAHC currently carries a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Boston Scientific (BSX - Free Report) , Globus Medical (GMED - Free Report) and ResMed (RMD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Boston Scientific’s shares have surged 69.3% in the past year. Estimates for the company’s earnings per share (EPS) have jumped 2.5% to $2.46 for 2024 and 2.2% to $2.77 for 2025 in the past 30 days. BSX’s earnings outpaced estimates in each of the trailing four quarters, delivering an average beat of 8.3%. In the last reported quarter, it posted an earnings surprise of 8.6%.
Estimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.